An interventional study of Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy and Bromocriptin 2.5mg, 2-3 times a day in Pituitary Tumor, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Not yet recruiting. Open to participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2024-08-15.
Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Not applicable, Interventional, and Treatment
The investigators carried out a multi-center comparative study, involving hospitals including the Second Affiliated Hospital of Zhejiang University School of Medicine, Peking Union Medical College Hospital, West China Hospital, Wenzhou First Hospital, and Li Huili Hospital. This study aimed to compare the efficacy of medication and surgery for specific subtypes of microadenomas and clearly defined macroadenomas (Knosp grades 0-2), in order to determine which is more effective and which has fewer benefits, thereby enhancing the evidence base.
200 studies on the registry are indexed under Pituitary Neoplasms; 51 are open to participants now.
This study's planned enrollment of 600 is above the median of 60 across 121 interventional studies indexed under Pituitary Neoplasms.
Browse Pituitary Neoplasms studies →Second Affiliated Hospital, School of Medicine, Zhejiang University is the lead sponsor of 1,047 studies on the registry; 502 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy
Procedure: Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy
Bromocriptin 2.5mg, 2-3 times a day
Drug: Bromocriptin 2.5mg, 2-3 times a day
Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy
Bromocriptin 2.5mg, 2-3 times a day
pituitary hormone levels
Recheck pituitary hormones (PRL, GH, ACTH, etc.)
Time frame: At 1, 3, 6, 9 and 12 months postoperatively
pituitary MRI
Recheck pituitary MRI
Time frame: At 1,6 and 12 months postoperatively
sexual function evaluation
Male:International Index of Erectile Function (IIEF-5); Female:Female Sexual Function Index (FSFI)
Time frame: At 1,6 and 12 months postoperatively
menstrual condition
There is currently no specific "Pituitary Tumor Menstrual Status Questionnaire" for evaluation. The investigators usually evaluate the impact of pituitary tumors on menstruation based on the participants clinical symptoms and the results of sex hormones
Time frame: At 6 and 12 months postoperatively
lactation
Serum prolactin levels
Time frame: At 1,6 and 12 months postoperatively
No study locations are listed for this record.
Start is estimated for Oct 2024; primary completion for Mar 2027, 29 months later.
Of 46 interventional studies with no phase under Pituitary Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 68. This study's planned 29 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Second Affiliated Hospital, School of Medicine, Zhejiang University →